CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The Canadian Cancer Trials Group (CCTG) is currently seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI) and Chair in Clinical Trials at Queens University.
Dr Branton was a dear friend of CCTG and a pioneer in the study of viral oncogenesis. His work has had far-reaching implications for cancer therapies and remain influential in the development of novel treatments. He played a pivotal role in shaping cancer research in Canada, serving as the inaugural Scientific Director of the Institute of Cancer Research at the Canadian Institutes of Health Research as well as spearheading the formation of the Canadian Cancer Research Alliance.
The Pharmacy Network Steering Committee is actively seeking a Pharmacist Representative for the Lung Disease Site Committee. The Pharmacy Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials.
Please review terms of reference at: https://www.ctg.queensu.ca/private/pharm_net/pharmacists-network
The Journal of Clinical Oncology has published ‘Correlative Science in the Cooperative Group System—Re-Engineering for Success,’ which proposes public-private partnerships to increase resources and process innovations to open access to tissue banks
The GA1 TOPGEAR trial results were presented at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain and simultaneously published in the
The European Society for Medical Oncology Congress (ESMO) 2024 congress was held September 13-17 in Barcelona, Spain and CCTG was there!
CCTG related presentations and posters
Late breaking results of the Canadian Cancer Trials Group (CCTG) BR31 study “A double-blind, placebo-controlled, randomized phase 3 trial of adjuvant durvalumab in completely resected non-small-cell lung cancer” were presented at the European Society for Medical Oncology (ESMO) Congress 2024.
